No OxyContin Comparison? Then No Priority Review For Targiniq ER
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA rejected Purdue’s request for priority review of Targiniq ER because the NDA did not show an improvement in abuse deterrence over the sponsor’s own reformulated OxyContin, but the agency noted advantages to having both formulations available.
You may also be interested in...
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.